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Abstract
Bladder cancer (BC) is one of the commonestmalignancies in the urinary system. Bladder cancer is
divided into non-muscle invasive bladder cancer (NMIBC) andmuscle invasive bladder cancer
(MIBC) according to the depth of invasion. Besides, the prognosis ofMIBC remains poor. Surgical
resection combinedwith radiotherapy or chemotherapy is the standard treatment forMIBC.
However, themajor obstacle that hinders successful chemotherapy is its lack of tumor targeting.Here,
we fabricated nanoparticles that respond to near-infrared laser irradiation in order to increase the
drug accumulation at the tumor sites and combine chemotherapywith photothermal therapy to
overcome challenges of bladder cancer treatment. IR780 andDoxorubicin (DOX)were loaded into
albumin nanoparticles (IR780-DOX@AlbuminNPs). In the process of IR780-DOX@AlbuminNPs
synthesis, the near-infraredmolecule IR780was used as the assemblymolecular bridge. Under
irradiation, the nanoparticles were decomposed due to the degradation of IR780while the release of
DOX increased. Nanoparticles can be ingested by tumor cells in a short time. The IR780-
DOX@AlbuminNPswere sensitive to near-infrared laser irradiation. Near-infrared laser irradiation
can promote the release of the drugs from the nanoparticles and induce a photothermal effect, thus
destroying the tumor cells. Given the excellent tumor-targeting ability and negligible toxicity to
normal tissue, IR780-DOX@AlbuminNPs can greatly increase the concentration of chemotherapeu-
tic drugs in tumor cells. This study combines photothermal therapy and chemotherapy to treatMIBC,
so as to avoid chemotherapy resistance, reduce the toxicity to normal cells, and achieve the purpose of





NPS nanoparticlesNMIBC: non-muscle invasive bladder cancer;











Original content from this
workmay be used under
the terms of the Creative
CommonsAttribution 4.0
licence.
Any further distribution of
this workmustmaintain
attribution to the
author(s) and the title of
thework, journal citation
andDOI.
© 2021TheAuthor(s). Published by IOPPublishing Ltd
Introduction
According to themost recent registry of cancer in 2019, the incidence of bladder cancer ranks second among
urinary system tumors, the fourth amongmale systemicmalignancies, and the eighth highestmortality rate [1].
Bladder cancer is divided into non-muscle invasive bladder cancer (NMIBC) andmuscle invasive bladder cancer
(MIBC) according to the depth of invasion.Most bladder cancers belong toNMIBC (75%–80%), butMIBC is
moremalignant thanNMIBC,whichmakes it one of the important factors threatening patients life [2, 3].
20%–30%of patients will experiencemalignant transformation or evenmetastasis of tumors, such as
lymphnodemetastasis, lungmetastasis, etc [4–6]. Radical bladder resection combinedwith chemotherapy is
the standard treatment forMIBC. The survival rate of patients with bladder cancer has not been improved
significantly for a long time [7, 8].
Doxorubicin (DOX), an antitumor drug, is commonly used against bladder cancer. However, the clinical
application ofDOX is restricted by its cardiotoxicity, although it remains as one of themost effective
chemotherapeutic antitumor agents since 1950s [9]. Its antitumor effect is achieved by intercalating intoDNA
helix and inhibiting the topoisomerase II enzyme activity [10–12]. IR780 is a lipophilic cationic near-infrared
smallmolecule [13], generally in the formof iodide. Itsmaximumabsorption peak is at around 780 nm. IR780
can penetrate deep into the tissue for imaging and obtain obvious signal contrast. Tumor cells of the spectrum
are preferentially taken up and selectively enter themitochondria of tumor cells. After IR780 is ingested by
tumor cells, it can be excited by near-infrared laser to generate high temperature, thereby killing tumor cells and
reducing damage to normal cells. Although IR780 possesses the above advantages, its hydrophobicity and
phototoxicity still limit its use in tumor therapy [14, 15].
Photothermal Therapy (PTT) is a promising therapeutic approach by using laser light to heat contrast
agents, leading to the thermal damage of tumor cells andmaking tumor cells degeneration and necrosis. [16].
Based on the good tissue penetration of near-infrared (NIR) laser, it is an ideal light source for photothermal
treatment [17, 18]. The high temperature produced by photothermal therapy can change the permeability of
biofilms, directly affecting the entry and exit ofNa+, K+, Ca2+, adenosine triphosphate and some proteins.
These factors can lead to the destruction of tumor cells; increaseDNAdamage and inhibit the repair ofDNA
damage.High temperaturewill not directly cause damage to theDNA chain, but can change the structure of
chromatin and inhibit its synthesis, thereby inhibitingDNA repair. High temperature disorganizes the
cytoskeleton, impairs cell function, and causes cell death [19].
Albumin is one of themost abundant plasma proteins and it keeps stable in the pH range of 4–9 and soluble
in 40% ethanol. Evenmore, no deleterious effects were observedwhen it was heated at 60 °C for up to 10 h
[20–22]. Albumin has various advantages, including biodegradability, non-immunogenicity, and
biocompatibility. Therefore, the use of albumin as a nanoparticle carrier can overcome the biological safety
deficiencies of othermaterials [23, 24].We found that the nanoparticles carrying photosensitizer IR780 can
produce photothermal and photodynamic effects under specific illumination, resulting in a significant anti-
tumor effect [25].
Therefore, in this study, we taken advantage of the lipophilic cationic properties of IR780 tomake it play the
role of assemblingmolecular bridges, and constructed a drug delivery systemwith albumin as the backbone,
which had controlled release of doxorubicin and IR780 and photothermal therapy. This delivery system can
reduce the toxicity of doxorubicin and IR780, and has the function offluorescence imaging.
Materials andmethods
Chemicals andmaterials
Doxorubicin (DOX) andBSAwere purchased fromAladdin co. (Shanghai, China). IR780was purchased from
Sigma-Aldrich co. (St. Louis, USA).MTTCell Proliferation andCytotoxicity AssayKit was obtained from
Beyotime (Shanghai, China). 1×Phosphate buffer solution (PBS) and deionizedwaterwere used in the
experiments. All other reagents were purchased fromNanjingWanqingChemical Glassware Instrument
Company and used as received.
Synthesis of IR780-DOX@AlbuminNPs
Firstly, we fully dissolve 100 mgBSA in 50 ml purewater, and add 100 μl of Dithiothreitol (DTT) solution
(10 mgml−1) to the BSA solution. After a period of reaction,DTTopens the hydrophobic space in the BSA.
Then 1 ml ofDOX inDMSO solution (1 mgml−1)was slowly added to the BSA solution under ultrasonic
condition. After wellmixing, 1 ml of IR780DMSO solution (1 mgml−1), was slowly added to the
aforementioned solution under ultrasonic condition, and a rotary evaporator was used to fully remove the
organic solvent to obtain IR780-DOX@AlbuminNPs.
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Characterization of IR780-DOX@AlbuminNPs
Wemeasured the characterization of the nanoparticles before and after laser excitation. Particle size was
measured by a Brookhaven BI-90Plus laser particle size analyzer. TheUV spectra of IR780, DOX, and albumin
nanoparticles weremeasured by an ultraviolet-visible spectrophotometer, to evaluate whether IR780 andDOX
were encapsulated in the nanoparticles. Transmission electronmicroscopywas used to observe themorphology
of the nanoparticles. Samples were prepared by dropping a suitable concentration of the nanoparticle solution
on a 200mesh coppermesh and dried overnight.
In vitro temperature curve
Wehave prepared free IR780 solution, albumin nanoparticle solution containing IR780 (IR780@AlbuminNPs),
albumin nanoparticle solution containingDOXand IR780 (IR780-DOX@AlbuminNPs), and PBS solution
(pH7.4). The concentration of IR780 is 50 μg ml−1. At room temperature, 808 nmnear-infrared laser
irradiationwas used to irradiate the samples for 0–150 s, and the photothermal effect of IR780-containing
nanoparticles was evaluated by a temperature probe.
Cell culture
Murine bladder carcinomaMB49 cells were obtained fromShanghai Institute of Biochemistry andCell Biology,
Chinese Academy of Sciences. The cell line wasmaintained in RPMI 1640 cell culturemedia supplementedwith
10% fetal calf serum (Hyclone, Logan,UT) and antimicrobial-antimycotic (Gibco/Invitrogen, Carlsbad, CA) in
a humidified incubator at 37 °C in an atmosphere composed of 5%CO2.The cell linewas transducedwith the
firefly luciferase gene by a lentivirus vector.
Cellular uptake
Themouse bladder cancer cell lineMB49 is used to evaluate the cell uptake efficiency. Cells incubatedwith
IR780-DOX@AlbuminNPs solution (both IR780 andDOX concentration are 1 μg ml−1) for a period of time,
and the nanoparticles that had not entered the cells werewashed awaywith PBS solution. The cells werefixed
with 4%paraformaldehyde, and then placed under a confocalmicroscope for observation to analyze the cellular
uptake of nanoparticles.
In vitro therapeutic efficacy of IR780-DOX@AlbuminNPs
Incubating themouse bladder cancer cell lineMB49with different concentrations of free IR780 solution, free
DOX solution and IR780-DOX@AlbuminNPs solution for a period of time, 808 nm laser was used to irradiate
part of the cell area of the experimental group for 3 min, and then cultured for 24 h. The cell viability was
evaluated byMTT assays bymeasuring the absorbance of the solution at 570 nm.
In vitro drug release
To study the release profile ofNPs, an appropriate amount of IR780-DOX@AlbuminNPs andDOX@Albumin
NPswere put into a dialysis bag separately, and placed in an Erlenmeyer flask. The Erlenmeyer flask isfilledwith
PBS solution (pH=7.4) as a releasemedium and placed in a constant temperature vibrator. The release of
IR780-DOX@AlbuminNPswas also studied by irradiationwith 808 nm laser. Samples (released solution)were
collected at the set time point (0–72 h), and replenish the same amount of releasedmedium. The release curve of
the drugwas got bymeasuring the characteristic absorption peak ofDOX in the released solution according to
the standard curve.
Establishment of a bladder cancermodel inC57BL/6mice
4–6weeks oldC57BL/6 femalemicewere anesthetized by intraperitoneal injection of sodiumpentobarbital,
and 2*106MB49 cells were planted into the left abdomen subcutaneously of eachmouse. The size of the tumor
wasmeasured every day.When observing the tumor growth to 100mm3,micewith a rounder tumor shape and
little difference in volumewere selected as an animalmodel for subsequent experiments.
Therapeutic efficacy of IR780-DOX@AlbuminNPs using bladder cancermodel
After selecting a suitablemouse bladder cancermodel, we defined the tumor size at this time as V0.We injected
saline, DOX@AlbuminNPs (2.5 mg kg−1DOX), IR780-DOX@AlbuminNPs (2.5 mg kg−1DOX, 4 mg kg−1
IR780), IR780@AlbuminNPs plus laser (4 mg kg−1 IR780), and IR780-DOX@AlbuminNPs plus laser
(2.5 mg kg−1DOX, 4 mg kg−1 IR780) groups intomice via tail vein injection. Each group contained fivemice.
After 48 h of administration, IR780@AlbuminNPs plus laser and IR780-DOX@AlbuminNPs plus laser groups
were irradiatedwith 808 nm laser. The tumor volumewasmeasured every 2 days after the administration and
the bodyweight change of themicewasmonitored.
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In vivo toxicity and biosafety
In order to verify the biosafety of the nanoparticles, C57BL/6micewere used here. Saline, DOX@AlbuminNPs
(2.5 mg kg−1DOX), IR780-DOX@AlbuminNPs (2.5 mg kg−1DOX, 4 mg kg−1 IR780), IR780@AlbuminNPs
plus laser (4 mg kg−1 IR780), and IR780-DOX@AlbuminNPs plus laser (2.5 mg kg−1 DOX, 4 mg kg−1 IR780)
groupswere injected intomice by tail vein. Each group contained threemice. After 48 h of administration,
IR780@AlbuminNPs plus laser and IR780-DOX@AlbuminNPs plus laser groupswere irradiatedwith 808 nm
laser. After 2weeks, themicewere killed, and the heart, liver, spleen, lung and kidneywere taken out, and the
organswere dehydrated and fixed, and thenHE stainingwas performed for histological analysis.
Results and discussion
Synthesis of IR780-DOX@AlbuminNPs
The synthesis process of IR780-DOX@AlbuminNPswas illustrated infigure 1. Firstly, we dissolved albumin in
purewater, whileDTTwas added to open the hydrophobic domain of albumin, andDOX can be loaded into
albumin by hydrophobic interaction [26]. Secondly, we use the hydrophobic and electrostatic effect of IR780 to
make it as amolecular bridge to tighten the spatial structure of albumin nanoparticles, andfinally get IR780-
DOX@AlbuminNPs [27]. Under irradiation, IR780 in the nanoparticles will be degraded, and produce a
photothermal effect, and also promote the release ofDOX.
Characterization of IR780-DOX@AlbuminNPs
The IR780-DOX@Albumin solutionwas spotted on the carbon-film copper net and dried overnight, and then
the shape and size were observed by transmission electronmicroscope; Dynamic Light Scattering (DLS)was
used to characterize the size and distribution of nanoparticles; the average particle size of IR780-DOX@Albumin
is 155.9 nm (figure 2(A)). After 808 nm laser is used to irradiate the nanoparticles, the average particle size of
IR780-DOX@Albumin is 235.7 nm, because laser irradiation accelerates the disintegration of nanoparticles. The
morphological changes of nanoparticles are shown infigure 2(B). Bymeasuring theUV absorption spectra of
IR780,DOX, IR780-DOX@Albumin nanoparticles, it can be found that IR780-DOX@Albumin nanoparticles
have characteristic absorption peaks at 497 nmand 780 nm,which proved that IR780 andDOXwere
successfully encapsulated into albumin nanoparticles (figure 3(A)).
In vitro temperature curve
Firstly, different concentrations of nanoparticle group and control solutionwere irradiated by using 808 nm
laser, while a temperature detector was used to detect the temperature change, the temperature curve of the
nanoparticles was draw after laser irradiation, to evaluate the photothermal effect of nanoparticles.We found
that IR780-DOX@AlbuminNPs and IR780@AlbuminNPs increased significantly after the 808 nm laser
Figure 1. Schematic illustration of the synthesis andworking principle of IR780-DOX@AlbuminNPs.
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irradiation. About 60 s later, the photothermal reaction of the nanoparticles reached the peak temperature and
could bemaintained for a period of time (figure 3(B)).
In vitro therapeutic efficacy of IR780-DOX@AlbuminNPs
Weuse theMTT assay to evaluate the anti-tumor therapeutic effect of IR780-DOX@AlbuminNPs in vitro. It can
be seen fromfigure 4(A) that under the same concentration of IR780-DOX@AlbuminNPs and free drugs, the
killing effect of IR780-DOX@AlbuminNPs on tumor cells is significantly better than that of free drugs on tumor
cells. The free IR780 andnanoparticle groupswere irradiatedwith 808 nm laser, and it was found that the free
IR780 and nanoparticle groups had significantly increased therapeutic effects on tumor cells. The results
confirmed that the nanoparticles had a good photothermal treatment effect.
Figure 2.Characterization of IR780-DOX@AlbuminNPs. (A)Particle size distribution data of IR780-DOX@AlbuminNPs before
and after laser irradiation. (B)Morphological changes of IR780-DOX@AlbuminNPs under transmission electronmicroscope before
and after laser irradiation.
Figure 3. (A)Optical properties of freeDOX, free IR780 and IR780-DOX@AlbuminNPs. (B)Temperature rise curve of PBS, free
IR780, IR780-DOX@AlbuminNPs and IR780-DOX@AlbuminNPs after laser irradiation.
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Cellular uptake
In order to verify the uptake of IR780-DOX@AlbuminNPs by cells,MB49 cells and IR780-DOX@AlbuminNPs
were co-cultured for 12 h, and then observed by a confocalmicroscope. It could be seen from figure 4(B) that
IR780-DOX@AlbuminNPs can be effectively taken up byMB49 cells andweremainly distributed in the
cytoplasm cytotoxicity and therapeutic efficacy of IR780-DOX@AlbuminNPs. (B)Observing cellular uptake in
DOX channel, IR780 channel, DAPI andmerge vision. Scale bars=20 μm. (eyepiece: 1×, objective lens: 20×).
In vitro drug release
An in vitro drug release studywas conducted to confirm the controlled-release pattern of DOXunder 808 nm
irradiation (figure 5(A)). It can be clearly found that as time increased, the cumulative release of DOX in vitro
increased.More importantly, the laser triggered the photothermal effect of IR780 in the nanoparticles, and the
cumulative release of DOXdrugs showed a significant growth (figure 5(B)). It was worth noting that the
cumulative DOX release of DOX@AlbuminNPswasmore than that of IR780-DOX@AlbuminNPs in the
same period.We speculate that this phenomenonwas related to the role of IR780 in nanoparticles. IR780
acted as amolecular bridge in the nanoparticles, making the space structure of the nanoparticlesmore
compact, andDOXwas not easy to release. This experiment verified the nature of nanoparticles in a
controlled releasemanner, andDOX can be triggered by near-infrared laser irradiation. From the results of
drug release experiments in vitro, we can combine photothermal therapy with chemotherapy drugs to
synergistically kill bladder cancer cells.
Therapeutic efficacy of IR780-DOX@AlbuminNPs using bladder cancermodel
Amouse bladder cancermodel have been established to evaluate the in vivo therapeutic effects of nanoparticles
on bladder cancer. After selecting a suitablemouse bladder cancermodel, we defined the tumor volume at this
time asV0.We injected saline, DOX@AlbuminNPs, IR780@AlbuminNPs+laser, and IR780-DOX@Albumin
NPs plus laser groups intomice via tail vein. The volume of the tumor and bodyweight weremeasured and
recorded (figure 6(A)) (figure 6(B)) every two days.When the tumor of themouse was too large on day 16th (V/
V0> 20), themousewas immediately killed and stopped recording (because of animal experiment ethics).
Experimental results show that the group IR780-DOX@AlbuminNPs plus laser have an excellent therapeutic
Figure 4.Cell viability and uptake of IR780-DOX@AlbuminNPs. (A) In vitro.
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effect on bladder tumors in vivo. The daily increase rate of V/V0 in the IR780-DOX@AlbuminNPs+laser
groupwas about 5.05% in the saline group. It was worth noting that the laser-irradiated IR780@AlbuminNPs
group inhibited tumorswell in the early stage, but due to the lack of the effect ofDOX, theV/V0 increased
significantly in the later stage. IR780-DOX@AlbuminNPs had a good photothermal and tumor suppression
efficiency, which achieved by near-infrared lasers to further suppress bladder cancer.
In vivo toxicity and biosafety
To evaluate the toxicity of the nanoparticles at thewhole-body level,major organswere harvested for
histological analysis. Therewere no obvious accumulation of nanoparticles and functional damage. Themajor
organs (heart, liver, spleen, lung, and kidney) of all the groups showed no noticeable histological changes
(figure 6(C)), suggesting the nanoparticles have no toxicity to the organs. Thereby, IR780-DOX@AlbuminNPs
have the possibility of clinical application
Figure 5. (A)The cumulative release ofDOX from IR780-DOX@AlbuminNPs under laser irradiation. (B)Observing cellular uptake
inDOXchannel, DAPI andmerge vision. Scale bars=20 μm. (eyepiece: 1×, objective lens: 20×).
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Conclusions
In this study, IR780-DOX@AlbuminNPswere synthesized to control the release ofDOXunder the action of
PTT to treat bladder cancer.We verified the biocompatibility, in vitro targeting, and photothermal properties of
the nanoparticles at the cellular level. At the same time, we studied the combination therapy and the toxicity of
the nanoparticles to normal tissues and tumor tissues at the animal level. IR780-DOX@AlbuminNPs can be
taken up by bladder cancer cellsmore than normal cells, so they have the less toxicity to normal cells and tissues.
This study combines the advantages of nanoparticle carriers, and IR780 acting as amolecular bridgewhichmade
the structure of the nanoparticlesmore compact, to solve the problems of photosensitizers insoluble inwater,
poor photostability and high toxicity, and reduce the toxicity of photosensitizer nanoparticles to normal cells.
Based on the optical treatment technology of nano-photosensitivematerials, PTT treatment effect of IR780 and
the tumor-killing effect ofDOXwere exerted to improve the treatment efficiency of bladder cancer.
Data availability statement
The data that support thefindings of this study are available upon reasonable request from the authors.
Figure 6.Therapeutic efficacy of IR780-DOX@AlbuminNPs using bladder cancermodel. (A)Construct an animalmodel of bladder
cancer, inject different therapeutic drugs into the tail vein, andmeasure the diameter of the tumor and (B) bodyweight. (C) In vivo
organ safety evaluation. Scale bar=100 μm. (eyepiece: 1×, objective lens: 5×).
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